Helen Marr

8.7k total citations
18 papers, 188 citations indexed

About

Helen Marr is a scholar working on Genetics, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Helen Marr has authored 18 papers receiving a total of 188 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Genetics, 8 papers in Oncology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Helen Marr's work include Chronic Lymphocytic Leukemia Research (11 papers), Cancer-related Molecular Pathways (7 papers) and Advanced Breast Cancer Therapies (6 papers). Helen Marr is often cited by papers focused on Chronic Lymphocytic Leukemia Research (11 papers), Cancer-related Molecular Pathways (7 papers) and Advanced Breast Cancer Therapies (6 papers). Helen Marr collaborates with scholars based in United Kingdom, Türkiye and Iraq. Helen Marr's co-authors include Elaine Willmore, Scott Marshall, Jonathan P. Wallis, Nick Bown, John Lunec, Peter Ganly, Eileen Merriman, Carmela Ciardullo, Paul Milne and Mark Smith and has published in prestigious journals such as Blood, International Journal of Molecular Sciences and British Journal of Cancer.

In The Last Decade

Helen Marr

17 papers receiving 186 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Helen Marr United Kingdom 10 65 64 64 43 32 18 188
Ilaria Scortechini Italy 10 100 1.5× 56 0.9× 44 0.7× 37 0.9× 174 5.4× 17 235
Ulrich Duehrsen Germany 7 125 1.9× 43 0.7× 72 1.1× 32 0.7× 85 2.7× 32 243
Anne‐Lise Ménard France 7 57 0.9× 26 0.4× 42 0.7× 36 0.8× 104 3.3× 15 187
Pedro Sánchez‐Godoy Spain 7 65 1.0× 99 1.5× 46 0.7× 33 0.8× 48 1.5× 18 220
Matthew W. Anderson United States 7 36 0.6× 72 1.1× 33 0.5× 168 3.9× 66 2.1× 12 281
Christos Demosthenous Greece 8 61 0.9× 71 1.1× 64 1.0× 47 1.1× 77 2.4× 19 202
Zoé Van de Wyngaert France 8 68 1.0× 81 1.3× 25 0.4× 26 0.6× 138 4.3× 22 191
Chongsheng Qian China 6 73 1.1× 74 1.2× 12 0.2× 30 0.7× 79 2.5× 24 212
Kota Yoshifuji Japan 6 53 0.8× 111 1.7× 25 0.4× 11 0.3× 57 1.8× 28 208
Wan-Jun Sun China 7 61 0.9× 44 0.7× 40 0.6× 61 1.4× 158 4.9× 23 211

Countries citing papers authored by Helen Marr

Since Specialization
Citations

This map shows the geographic impact of Helen Marr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helen Marr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helen Marr more than expected).

Fields of papers citing papers by Helen Marr

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Helen Marr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helen Marr. The network helps show where Helen Marr may publish in the future.

Co-authorship network of co-authors of Helen Marr

This figure shows the co-authorship network connecting the top 25 collaborators of Helen Marr. A scholar is included among the top collaborators of Helen Marr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Helen Marr. Helen Marr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Wallis, Jonathan P., Helen Marr, Scott Marshall, et al.. (2025). Targeting the MDM2-p53 Interaction with Siremadlin: A Promising Therapeutic Strategy for Treating TP53 Wild-Type Chronic Lymphocytic Leukemia. Cancers. 17(2). 274–274. 2 indexed citations
2.
Walewska, Renata, Toby A. Eyre, Adrian Bloor, et al.. (2025). 2025 British Society for Haematology Guideline for the treatment of chronic lymphocytic leukaemia. British Journal of Haematology. 207(6). 2296–2313.
3.
Nakjang, Sirintra, Jonathan P. Wallis, Helen Marr, et al.. (2024). RNA Sequencing Reveals Candidate Genes and Pathways Associated with Resistance to MDM2 Antagonist Idasanutlin in TP53 Wild-Type Chronic Lymphocytic Leukemia. Biomedicines. 12(7). 1388–1388. 4 indexed citations
4.
Ciardullo, Carmela, Jonathan P. Wallis, Helen Marr, et al.. (2023). Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 Inhibition. International Journal of Molecular Sciences. 24(3). 2410–2410. 11 indexed citations
5.
Wallis, Jonathan P., Helen Marr, Scott Marshall, et al.. (2023). SF3B1 Mutations Are Associated with Resistance to Non-Genotoxic MDM2 Inhibition in Chronic Lymphocytic Leukemia. International Journal of Molecular Sciences. 24(14). 11335–11335. 7 indexed citations
6.
Taha, Yusri, Adam B. Evans, Ewan Hunter, et al.. (2021). Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy. Annals of Clinical Microbiology and Antimicrobials. 20(1). 85–85. 22 indexed citations
7.
Eyre, Toby A., John C. Riches, Piers Patten, et al.. (2021). Richter transformation of chronic lymphocytic leukaemia: a British Society for Haematology Good Practice Paper. British Journal of Haematology. 196(4). 864–870. 10 indexed citations
8.
Barrow, Timothy M., Sirintra Nakjang, Susan J. Tudhope, et al.. (2020). Epigenome-wide analysis reveals functional modulators of drug sensitivity and post-treatment survival in chronic lymphocytic leukaemia. British Journal of Cancer. 124(2). 474–483. 15 indexed citations
9.
Milne, Paul, Charlotte S. Wilhelm-Benartzi, Michael R. Grunwald, et al.. (2019). Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia. Blood Advances. 3(20). 3052–3061. 17 indexed citations
10.
Ciardullo, Carmela, Wei‐Yu Lin, Jonathan P. Wallis, et al.. (2019). Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells. Haematologica. 104(12). 2429–2442. 23 indexed citations
11.
Sinclair, Paul, Helen Blair, Sarra Ryan, et al.. (2018). Dynamic clonal progression in xenografts of acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21. Haematologica. 103(4). 634–644. 9 indexed citations
12.
Fordham, Sarah, Helen J. Blair, Ruth Plummer, et al.. (2018). Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase. Blood Advances. 2(10). 1157–1169. 31 indexed citations
13.
Ciardullo, Carmela, Jonathan P. Wallis, Helen Marr, et al.. (2016). The p53-MDM2 Antagonist RG7388 Activates p53 and Induces a Predominantly Pro-Apoptotic Gene Expression Signature in Chronic Lymphocytic Leukemia. Blood. 128(22). 893–893. 1 indexed citations
14.
Willmore, Elaine, Aaron Gardner, Susan J. Tudhope, et al.. (2016). Targeting Ikkα in CLL: Inhibition of Non-Canonical NF-κb Signaling Decreases Survival and Proliferation of CD40L-Stimulated Primary CLL Cells. Blood. 128(22). 3959–3959. 1 indexed citations
15.
Tudhope, Susan J., Evan A. Mulligan, Jill V. Hunter, et al.. (2012). P B S-1086, a “Pan-Rel” Inhibitor, Decreases Viability of Chronic Lymphocytic Leukemia Cells. Blood. 120(21). 867–867. 2 indexed citations
16.
Osborne, Wendy, Gail Jones, Graham Jackson, & Helen Marr. (2012). Myeloproliferative disorders in older people. Reviews in Clinical Gerontology. 22(2). 108–118. 1 indexed citations
17.
Marr, Helen, et al.. (2009). Successful treatment of transplant-associated microangiopathy with rituximab.. PubMed. 122(1292). 72–4. 18 indexed citations
18.
Ganly, Peter, et al.. (2008). Successful Treatment of Transplant Associated Microangiopathy with Rituximab. Blood. 112(11). 4337–4337. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ilaria Scortechini Breakdown of academic impact, for papers by Ulrich Duehrsen Breakdown of academic impact, for papers by Anne‐Lise Ménard Breakdown of academic impact, for papers by Pedro Sánchez‐Godoy Breakdown of academic impact, for papers by Matthew W. Anderson Breakdown of academic impact, for papers by Christos Demosthenous Breakdown of academic impact, for papers by Zoé Van de Wyngaert Breakdown of academic impact, for papers by Chongsheng Qian Breakdown of academic impact, for papers by Kota Yoshifuji Breakdown of academic impact, for papers by Wan-Jun Sun
Rankless by CCL
2026